Can epoetin alfa maintain ribavirin doses in patients with hepatitis C virus on combination therapy?
Heiner Wedemeyer and Michael P Manns*
Correspondence *Department of Gastroenterology and Hepatology, Medical School of Hannover, Carl-Neuberg-Strasse 1, 30623 Hannover, Germany
Email Manns.Michael@mh-hannover.de
This article has no abstract so we have provided the first paragraph of the full text.
The introduction of interferon 
plus ribavirin combination therapy for HCV infection and the development of PEGYLATED INTERFERON has led to an impressive increase in virologic responses from <10% to >50% of cases.1, 2 It has become evident that there is a close correlation between sustained treatment responses in HCV genotype 1 infection and the dose of ribavirin administered, with better responses with higher doses.
Full text of this article is available with one of the following:
- Membership of the American College of Gastroenterology. If already a member, please login.
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
